We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Capping Laboratory Diagnostics Strategy, Siemens to Acquire Dade Behring for $7 Billion

By HospiMedica staff writers
Posted on 30 Jul 2007
Print article
Further building on its bold quest for global leadership in the dynamic in-vitro diagnostics sector, initiated with its recent acquisitions of Bayer Diagnostics and DPC, Siemens Medical Solutions has agreed to buy Dade Behring for about US$7 billion. Subject to regulatory approvals, the transaction is expected to close by March 2008.

With annual revenues of about $1.7 billion and some 6,400 employees in 35 countries, Dade Behring (Deerfield, IL, USA) is a global leader in laboratory diagnostics, including clinical chemistry testing, immunodiagnostics, hemostasis testing, and microbiology.

Siemens Medical Solutions (Erlangen, Germany), one of the world's largest providers of healthcare products and systems, and a unit of technology giant Siemens AG (Munich, Germany), employs more than 41,000 people in some 130 countries and reported sales of EUR 8.23 billion in fiscal 2006.

With the proposed acquisition, Siemens Medical Solutions aims at advancing its vision of becoming the global leader in full-range medical diagnostics – incorporating imaging diagnostics, clinical laboratory diagnostics, and healthcare information technology (IT) – all offered from a single source and under the Siemens umbrella.

Erich R. Reinhardt, president of Siemens Medical Solutions, pointed out, the planned acquisition of Dade Behring complements our current capabilities and offers us the unique opportunity to create an unparalleled portfolio of products and services, and become world market leader in comprehensive clinical laboratory diagnostics.

Siemens' foray into the relatively fast-growing and high-margin laboratory diagnostics field was first launched in mid-2006, when Diagnostics Products Corp. (DPC), a major player in immunodiagnostics, was acquired for $1.86 billion. This was soon followed with Siemens agreeing to buy Bayer AG's diagnostics division for EUR 4.2 billion. The acquisition of Bayer Diagnostics - with 2006 sales exceeding EUR 1.5 billion – elevated Siemens' emerging laboratory diagnostics group to the top ranks of the industry, a position to be further enhanced with the proposed acquisition.


A 'homecoming' for the venerable Behring imprint

Dade Behring was formed in 1997 by the merger of two venerable names from across two continents – Behring Diagnostics, founded in 1904 in Marburg, Germany, by the legendary scientist Dr. Emil Behring; and Dade International, founded in 1949 in Miami, FL, USA, by blood bank pioneer Dr. John Elliott.

Considered the father of modern immunology and serology, Dr. Behring discovered the diphtheria antitoxin and brought about other breakthroughs related to infectious diseases, earning him the first Nobel Prize for Medicine in 1901. Behringwerke, founded by Dr. Behring in the university town of Marburg to commercialize his scientific developments, expanded into diagnostic products in 1935 and ever since formed a pillar of the laboratory diagnostics sector in Germany.

Industry sources commented that Siemens might be paying a premium for
bringing the illustrious Behring name back home. In its claim for
global leadership, they expect Siemens' newly-minted laboratory
diagnostics powerhouse to fully capitalize on the value of the Behring
image.


GE's proposed Abbott Diagnostics acquisition is called off

The benefits of merging in-vitro (laboratory) and in-vivo (imaging) diagnostics under one roof, did not go unnoticed by GE Healthcare (Chalfont St. Giles, UK), a principal Siemens rival in the global healthcare sector. Accordingly, in January 2007, GE Healthcare initiated an agreement to buy market leader Abbott Laboratories' in-vitro and point-of-care (POC) diagnostics segment – a business that showed sales of $2.7 billion in 2006 – for $8.13 billion. However, the financial community was displeased with what it viewed as an excessive price tag, while ongoing regulatory problems in the manufacturing area raised additional hurdles. As a result, the proposed acquisition was called off in mid-July.


Related Links:
Siemens Medical Solutions
Dade Behring
GE Healthcare
Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Automated Blood Typing System
IH-500 NEXT
New
Vibrio Cholerae O1/O139 Rapid Test
StrongStep Vibrio Cholerae O1/O139 Antigen Combo Rapid Test
New
Herpes Virus Test
Human Herpes Virus (HHV-6) Real Time PCR Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.